Perimenopause is the transition before periods stop, and it happens as a sequence rather than a single event. Inhibin falls first, FSH rises in response, progesterone declines as ovulation becomes unreliable — and estrogen changes last, swinging rather than falling. That order explains why a woman can feel unmistakably different while her blood tests come back normal.

Key points

●      Perimenopause is fluctuation, not steady decline.

●      Estradiol is the last thing to change, which is why early testing misleads.

●      Progesterone falls first among the hormones you'd notice — and takes sleep with it.

●      Fat rises and muscle falls at the same time, but the scale can stay still while your body changes.

●      Around 70% of women get musculoskeletal symptoms, and most are never told they're related.

What is perimenopause, exactly?

It's the transition leading up to your final period — defined by hormones fluctuating rather than steadily falling.

Estrogen in perimenopause doesn't decline in a straight line. It swings — sometimes higher than in your thirties, sometimes very low, occasionally within the same month [1].

Which is why symptoms are erratic rather than progressive. A good six weeks followed by a terrible one isn't a sign you're imagining it. Fluctuation is the mechanism, and it's the single most confusing thing about this phase.

How do I know if I'm in it?

By what your cycles are doing — not by a blood test.

The international staging framework, STRAW+10, uses menstrual bleeding patterns as the primary criterion, with hormones as supporting evidence only [2]. Early perimenopause is defined by cycle length varying by seven days or more. Late perimenopause by skipping periods for 60 days or more.

Menopause itself is twelve consecutive months without a period — so perimenopause is only fully identifiable in hindsight.

What's actually happening to my hormones?

A sequence, and the order matters more than any single value.

Inhibin falls first. Produced by developing follicles, inhibin declines several years before the final period — while estradiol is still being maintained [3]. Which of the two inhibins moves first is still debated; that they move before estradiol is not.

FSH rises in response, because inhibin was part of what held it down. Modestly at first, then substantially in late perimenopause [3].

Progesterone falls next — and this is the one you feel. From the late thirties or early forties, ovulation becomes unreliable. Some cycles release no egg, and without ovulation there's no corpus luteum, and without a corpus luteum, no progesterone [1].

That matters more than it sounds. Progesterone's metabolite allopregnanolone acts on GABA-A receptors — the same system targeted by anti-anxiety and sleep medication. When it falls, sleep and anxiety are usually the first things to change, and waking at 2am fully alert is one of its clearest signatures.

Estradiol changes last, and it swings. Because estrogen can still spike in cycles where ovulation didn't happen, the balance between the two shifts well before either is low [1,3].

And cortisol rises while the ovarian hormones fall [1].

What about testosterone and DHEA?

They're on a separate clock — age, not menopause.

Testosterone doesn't track the transition. It declines slowly with age instead, and your ovaries keep producing it after your periods stop [4]. Women are told both that menopause crashes it (it doesn't) and that it's irrelevant to them (it isn't — it supports vascular response, sensation, muscle, and arousal physiology).

DHEA has been falling since around age 30, at roughly 1–2% per year [5]. By perimenopause that's been underway for a decade.

One thing worth knowing about DHEA results. Laboratory reference ranges are age-adjusted, so your result is compared with other women your age. Falling "within range" means your level is typical for your age group — not that it's adequate for what your tissue needs. Those are different claims, and they get conflated routinely.

And SHBG decides how much you can actually use — the carrier protein binding both testosterone and estrogen [4].

Before you ask for a testosterone test: standard assays measure poorly at concentrations normal in women, so a result may not mean what it appears to. There's no established relationship between a woman's level and her symptoms. Current international consensus recognizes one evidence-based indication for testosterone therapy in women: low sexual desire causing distress [6].

Why has my body changed when the scale hasn't?

Because fat and muscle are moving in opposite directions at the same time, and they cancel out on the scale.

SWAN measured body composition by DXA scan in 1,246 women and anchored the results to the date of the final period [7].

About two years before the final period, the rate of fat gain doubled — roughly from 1% to 1.7% per year. At the same moment, lean mass began to decline. Both continued until about two years after the final period, then flattened out [7].

Meanwhile body weight climbed in a straight line the whole way through, with no acceleration at the transition at all [7].

Which is the finding worth sitting with: you can be gaining fat and losing muscle while the scale says nothing is happening, because the two changes balance out. So a woman who says her body has changed shape while her weight is stable is describing something real and measured.

Three things follow. The window is defined — roughly four years, from two before the final period to two after — and it ends. BMI becomes less informative during and after it, because the same number now represents a different body. And since lean mass is what's being lost, resistance training and protein matter more in this window than at any earlier point.

One caveat: these patterns weren't identical across groups. Black and White women showed similar trajectories; Japanese women lost lean mass without gaining fat; Chinese women gained lean and lost fat after menopause [7].

Why do my joints hurt?

Because there's a musculoskeletal syndrome of menopause, and almost nobody is told about it.

It affects an estimated 70% of midlife women, with about a quarter experiencing severe symptoms [8]. It includes joint pain and stiffness, loss of muscle mass, loss of bone density, increased tendon and ligament injury, and adhesive capsulitis — frozen shoulder [8].

Frozen shoulder affects women around four times more often than men and peaks between 40 and 60. It has not traditionally been connected to menopause, and it can be genuinely disabling.

The most useful fact here: around 40% of affected women have no structural findings on imaging [8]. So a normal scan doesn't mean nothing is wrong — it means the problem isn't structural.

The term was proposed recently, precisely because these symptoms were going unrecognized [8]. If your joints started hurting in your forties and nobody connected it to anything, that connection now has a name.

Why won't a blood test just tell me?

Because of the sequence above. In early perimenopause, estradiol hasn't changed yet. A woman can be genuinely, measurably in transition and have an entirely normal estradiol result — because estradiol is the last domino, not the first.

A single estradiol value is close to meaningless during this phase — low, normal, or high depending on the day. No single FSH value places you in a stage either [2].

So what should be tested?

Things that aren't hormones — because every symptom of perimenopause is also a symptom of something else.

Fatigue, low mood, brain fog, temperature intolerance and hair changes all appear in hypothyroidism, iron deficiency, low B12, vitamin D deficiency, insulin resistance and depression.

This is the most practically important sentence in this article. A woman told "it's just perimenopause" who actually has an underactive thyroid, or is iron-deficient, goes untreated for something straightforward.

Ask for thyroid function, ferritin, B12 and vitamin D — not to diagnose perimenopause, but to rule out the conditions that look exactly like it. They can also coexist with it.

Can vulvar and vaginal symptoms start before my periods stop?

Yes — and this is what most women aren't told.

Nearly everything written about vulvar and vaginal change is framed as happening after menopause. Large European surveys found a substantial proportion of affected women report onset around the transition rather than well after it [9,10], and Spanish data describe genitourinary symptoms affecting roughly one in two perimenopausal and postmenopausal women [11].

So dryness, irritation or discomfort with sex arriving while you're still having periods is not early, not unusual, and not a sign something else is wrong. It matters practically, because a woman still menstruating is frequently told her symptoms can't be hormonal — and that delays help.

→ What Causes Vaginal Dryness After Menopause · Why Does Sex Hurt in Midlife?

Why are my eyes and mouth dry too?

Because the same tissue type is involved, in more than one place.

Mucosal surfaces — mouth, eyes, vulva — share hormone responsiveness. In perimenopausal women, dry mouth, taste disturbance and burning mouth are reported alongside the more familiar symptoms [12]. Dry eye becomes more common in the same years.

This reframes the whole thing usefully. Vulvar and vaginal dryness isn't an isolated genital problem — it's one instance of a change happening across hormone-responsive mucosa. Which is why a woman may notice her eyes, mouth and vulva changing in the same period and never think to mention them together.

(The evidence here is early — the oral symptom study included 43 women [12]. The pattern is clinically recognized; the mechanism is not fully worked out.)

→ How Vulvar Tissue Makes Its Own Hormones

Why do I feel foggy and unfocused?

Because something measurable happens to cognition during the transition — and it's been documented.

60% of women report memory problems during the menopause transition [13]. For a long time that was treated as subjective.

Then SWAN measured it, following 2,362 women for four years. The finding was specific and rather elegant: on tests given repeatedly, most people improve, because practice helps. Premenopausal, early perimenopausal and postmenopausal women all showed that improvement.

Women in late perimenopause did not. Their scores stopped climbing [13].

They weren't losing what they knew. They had stopped learning at the rate they used to — and the ability to improve with practice returned after menopause [13].

Isn't that just bad sleep and stress?

Apparently not, and this is the most interesting finding in this area.

A follow-up analysis tested exactly that — whether depressive symptoms, anxiety, sleep disturbance and hot flushes could account for the change. They couldn't [14]. Mood symptoms had a small effect on processing speed, but none of these explained the loss of learning.

So the fog isn't simply downstream of a bad year. Something else is happening, and it isn't yet accounted for.

Is this "menopausal ADHD"?

That label is misleading and worth resisting.

What's documented is a time-limited change in the ability to hold attention and consolidate new learning during hormonal instability. That isn't an attention deficit disorder — it's specific, identifiable and largely reversible. The name turns something temporary into what sounds like a permanent condition of the person.

Clinical guidance emphasizes these changes are common, generally modest, and not a sign of dementia [15] — while taking seriously that they can be genuinely disruptive.

Why has my interest in sex changed already?

Because the systems behind desire don't change together — and the one generating wanting shifts first.

Drive is typically affected first — the circuitry generating wanting runs partly on dopamine signaling sensitive to estrogen, and perimenopause is when estrogen becomes erratic, long before it becomes low.

Access is affected by the same attentional instability described above. An erotic thought that arrives but can't hold your attention doesn't go anywhere.

Capacity usually holds up longer, because vulvar and vaginal tissue can produce hormones locally from DHEA rather than depending entirely on the ovaries.

That mismatch is why so many women describe the same odd combination: I don't think about it, but when we do, everything still works. It's expected, explainable, and not a failure of desire.

→ Why Does Desire Decline in Midlife?

Is it normal to feel this low?

Low mood and anxiety are more common during perimenopause — and that's a reason to seek help, not to wait it out.

Falling progesterone removes a source of GABA-A activity that has a calming effect, cortisol rises, and sleep fragments. Those changes interact in a way that's hard to untangle from life circumstances.

Please talk to someone if low mood has lasted more than two weeks, you've lost interest in things you normally enjoy, you're struggling to function day to day, or you're having thoughts of harming yourself.

That last one needs same-day help. This is treatable, and not something to manage alone.

What can I actually do now?

Track the pattern. Symptoms, timing, and where you are in your cycle. Because perimenopause fluctuates, a few months of notes tell a clinician far more than one blood test.

Name the cluster. Symptoms arrive together — sleep, mood, focus, joints, cycle changes, vulvar symptoms, desire. Presenting them as one picture rather than seven complaints changes the conversation.

Ask for the mimics to be excluded. Thyroid, ferritin, B12, vitamin D.

Protect lean mass. Resistance training and adequate protein matter more in this four-year window than at any earlier point [7].

Don't accept "you're too young." Perimenopause commonly begins in the forties and can begin earlier.

Get anything unusual examined. Fluctuating hormones explain a great deal but not everything. Bleeding between periods, bleeding after sex, very heavy bleeding, a lump or a skin change needs assessment on its own terms.

 

Affecting some women:  Allergies and Autoimmune

Why do my allergies seem worse?

Because estrogen directly activates mast cells — the cells that release histamine — and because the immune system itself changes during the transition.

Two things are happening at once. Mast cells carry estrogen receptors, and estradiol at ordinary physiological concentrations triggers partial degranulation through a membrane estrogen receptor and calcium influx, while also amplifying the degranulation caused by allergens [13]. The effect disappears in cells lacking that receptor, which is how we know the receptor is doing it. Progesterone appears to work the other way, restraining histamine release.

Underneath that, the hormonal shift alters immune regulation more broadly — the balance of inflammatory and anti-inflammatory signaling changes as estrogen, progesterone and androgens all move [14]. So it isn't only that mast cells become more reactive; the system they sit inside is being reset at the same time.

Mast cells carry estrogen receptors. Estradiol at ordinary physiological concentrations triggers partial degranulation through a membrane estrogen receptor and calcium influx, and it amplifies the degranulation caused by allergens [13]. The effect disappears in cells lacking that receptor, which is how we know the receptor is doing it. Progesterone appears to work the other way, restraining histamine release. 

Mast cells sit in skin, airways, gut and the genitourinary tract — the tissues most exposed to the outside world. So when estrogen swings, they swing with it.

Women describe this as new or worsening allergies, itching, flushing, hives, headaches or reactions to foods and products they used to tolerate. Many are told it's unrelated to perimenopause.

Being clear about the evidence: the cellular mechanism is well established. What hasn't been studied is whether this produces a definable clinical syndrome in perimenopausal women. Terms like "histamine intolerance" and mast cell activation syndrome are used widely and have contested diagnostic criteria. So: a solid mechanism, a plausible connection, and a clinical picture nobody has properly investigated.

What about autoimmune conditions?

Several have their peak incidence around the menopausal transition, which surprises people — including clinicians.

Roughly 80% of people with autoimmune disease are women. And the timing isn't evenly spread across life:

Multiple sclerosis peaks in the perimenopausal age group, with more severe disease after menopause [14]. Lupus was long described as a disease of women of childbearing age, until data showed peak incidence in women around the time of menopause — flares become less frequent afterwards but each does more damage [14,15]. Rheumatoid arthritis tends to worsen, with early menopause associated with higher risk [14,15]. Psoriasis commonly exacerbates after menopause [14].

The picture isn't uniform — some features improve while others worsen, and the literature is explicit that trends aren't consistent across every manifestation [15].

One differential worth knowing

If you have dry eyes, dry mouth and vaginal dryness together, that combination deserves investigation rather than assumption.

It's the classic presentation of Sjögren's syndrome, an autoimmune condition affecting moisture-producing glands — and Sjögren's tends to worsen at menopause, with vaginal dryness particularly prominent [14].

Perimenopause can produce all three. So can Sjögren's. They're distinguishable by testing, and only one of them needs an autoimmune workup. If the dryness is severe, came on quickly, or is out of proportion to everything else, say so and ask.

Frequently asked questions

How long does perimenopause last? It varies — commonly several years. Because it's defined retrospectively, the length is usually only clear afterwards.

Can I be in perimenopause with regular periods? Yes. Progesterone can be falling while cycles are still regular, and symptoms often begin then [1].

Will a blood test tell me? Not reliably. Estradiol is the last hormone to change, so early testing can be entirely normal in a woman clearly in transition [2,3].

Why has my body changed but not my weight? Fat gain accelerates while lean mass declines, and the two offset each other on the scale [7].

Why do my joints hurt, and why was my scan normal? Around 70% of midlife women experience musculoskeletal symptoms, and roughly 40% of those affected have no structural findings on imaging [8].

Is brain fog permanent? The evidence suggests not. In SWAN, the ability to improve with practice returned after menopause [13].

Can vulvar symptoms really start this early? Yes. Surveys find onset commonly around the transition rather than well after it [9,10,11].

What's established, and what isn't

Established. Inhibin falls in early perimenopause before estradiol changes significantly; FSH rises subsequently [3]. STRAW+10 stages the transition on bleeding patterns, with hormones as supporting criteria only [2]. Fat gain accelerates and lean mass declines from about two years before the final period until two years after, while total weight rises linearly throughout [7]. Musculoskeletal symptoms affect an estimated 70% of midlife women [8]. Testosterone declines with age rather than with menopause [4]. DHEA declines from around age 30 [5]. 60% of women report memory problems during the transition, and SWAN found a measurable, time-limited loss of learning improvement in late perimenopause [13], not accounted for by mood, sleep or vasomotor symptoms [14]. Genitourinary symptoms affect a large proportion of perimenopausal as well as postmenopausal women [9,10,11].

Inferred. That Drive, Access and Capacity change asynchronously with Drive affected earliest. This is the core claim of the Drive–Access–Capacity Model — grounded in established physiology and offered as a way to organise the problem, not a measured finding [16]. That oral, ocular and vulvovaginal dryness reflect a shared mucosal mechanism — clinically recognised, mechanistically incomplete, and studied so far only in small samples [12].

Not established. Any test identifying which system is limiting for an individual. Any accepted mechanism for the perimenopausal cognitive change [14]. Which of the two inhibins declines first, which remains debated.

Educational note: This content is provided for educational purposes only and is not intended to diagnose, treat, cure, or prevent any medical condition. Persistent or new symptoms should be evaluated by a qualified healthcare provider.

By Laura Kelly, DAOM, L.Ac., Dipl. OM — Developer of the Drive–Capacity Model of midlife female sexual function. A California-licensed primary care provider and nationally board-certified clinician with a clinical focus on women’s health and healthy aging. Research Scholar, Ronin Institute. ORCID: 0000-0001-6586-7308.  More about Dr. Kelly

Published 8/2026 · Last reviewed 8/2026

References

1. Grub J, Süss H, Willi J, Ehlert U. Steroid hormone secretion over the course of the perimenopause: findings from the Swiss Perimenopause Study. Front Glob Womens Health. 2021;2:774308. doi:10.3389/fgwh.2021.774308
2. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168.
3. Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, Green A, Dennerstein L. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf). 1998;48(6):809–813. doi:10.1046/j.1365-2265.1998.00482.x
4. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8):2832–2838. doi:10.1210/jcem.85.8.6740
5. Yiallouris A, Tsioutis C, Agapidaki E, Zafeiri M, Agouridis AP, Ntourakis D, Johnson EO. Adrenal aging and its implications on stress responsiveness in humans. Front Endocrinol. 2019;10:54. doi:10.3389/fendo.2019.00054
6. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603
7. Greendale GA, Sternfeld B, Huang MH, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi:10.1172/jci.insight.124865
8. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466–472. doi:10.1080/13697137.2024.2380363
9. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19(2):188–197. doi:10.3109/13697137.2015.1107039
10. Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018;21(3):286–291. doi:10.1080/13697137.2018.1446930
11. Moral E, Delgado JL, Carmona F, et al; GENISSE Study Investigators. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018;21(2):167–173.
12. Taga T, Ito K, Takamatsu K, Ogawa M, Funayama S, Inoue M. Menopausal symptoms are associated with oral sensory complaints in perimenopausal women: an observational study. BMC Womens Health. 2021;21(1):262. doi:10.1186/s12905-021-01401-6
13. Zaitsu M, Narita S, Lambert KC, et al. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007;44(8):1977–1985.
14. Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol (Lausanne). 2019;10:265. doi:10.3389/fendo.2019.00265
15. Marder W, Vinet É, Somers EC. Rheumatic autoimmune diseases in women and midlife health. Womens Midlife Health. 2015;1:11. doi:10.1186/s40695-015-0012-9
16. Greendale GA, Huang MH, Wight RG, Seeman T, Luetters C, Avis NE, Johnston J, Karlamangla AS. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850–1857. doi:10.1212/WNL.0b013e3181a71193
17. Greendale GA, Wight RG, Huang MH, Avis N, Gold EB, Joffe H, Seeman T, Vuge M, Karlamangla AS. Menopause-associated symptoms and cognitive performance: results from the Study of Women's Health Across the Nation. Am J Epidemiol. 2010;171(11):1214–1224.
18. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional's guide for decision-making and counseling on cognition. Climacteric. 2022;25(6):570–578. doi:10.1080/13697137.2022.2122792
19. Kelly L. The drive–capacity model: a systems biology framework for midlife female sexual function. Research Connections. 2026;1(2):vmag023. doi:10.1093/rescon/vmag023